JP2019524253A - 局所領域注入のための植込み可能な医療装置 - Google Patents
局所領域注入のための植込み可能な医療装置 Download PDFInfo
- Publication number
- JP2019524253A JP2019524253A JP2019502558A JP2019502558A JP2019524253A JP 2019524253 A JP2019524253 A JP 2019524253A JP 2019502558 A JP2019502558 A JP 2019502558A JP 2019502558 A JP2019502558 A JP 2019502558A JP 2019524253 A JP2019524253 A JP 2019524253A
- Authority
- JP
- Japan
- Prior art keywords
- microfluidic
- cover
- microfluidic chip
- medical device
- blood vessel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 32
- 239000007924 injection Substances 0.000 title claims abstract description 32
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 45
- 239000012530 fluid Substances 0.000 claims abstract description 39
- 238000005070 sampling Methods 0.000 claims abstract description 16
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 15
- 108020004459 Small interfering RNA Proteins 0.000 claims description 14
- 230000000340 anti-metabolite Effects 0.000 claims description 13
- 229940100197 antimetabolite Drugs 0.000 claims description 13
- 239000002256 antimetabolite Substances 0.000 claims description 13
- 229910052697 platinum Inorganic materials 0.000 claims description 12
- 231100000782 microtubule inhibitor Toxicity 0.000 claims description 10
- 229940122255 Microtubule inhibitor Drugs 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000003909 protein kinase inhibitor Substances 0.000 claims description 9
- 239000003972 antineoplastic antibiotic Substances 0.000 claims description 8
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 7
- 229940043355 kinase inhibitor Drugs 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 239000002534 radiation-sensitizing agent Substances 0.000 claims description 6
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 5
- 206010027457 Metastases to liver Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 229940100198 alkylating agent Drugs 0.000 claims description 5
- 239000002168 alkylating agent Substances 0.000 claims description 5
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 5
- 229940121647 egfr inhibitor Drugs 0.000 claims description 3
- 239000002525 vasculotropin inhibitor Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 2
- 239000002924 silencing RNA Substances 0.000 claims 3
- 239000000758 substrate Substances 0.000 description 27
- 230000001225 therapeutic effect Effects 0.000 description 27
- 238000011282 treatment Methods 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 15
- 210000000056 organ Anatomy 0.000 description 14
- 239000007788 liquid Substances 0.000 description 10
- 238000002513 implantation Methods 0.000 description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 229960002949 fluorouracil Drugs 0.000 description 7
- -1 polydimethylsiloxane Polymers 0.000 description 7
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 6
- 239000004713 Cyclic olefin copolymer Substances 0.000 description 6
- 229930012538 Paclitaxel Natural products 0.000 description 6
- 229920000954 Polyglycolide Polymers 0.000 description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229960001592 paclitaxel Drugs 0.000 description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 6
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 6
- 229920001610 polycaprolactone Polymers 0.000 description 6
- 239000004632 polycaprolactone Substances 0.000 description 6
- 229920000139 polyethylene terephthalate Polymers 0.000 description 6
- 239000005020 polyethylene terephthalate Substances 0.000 description 6
- 239000004633 polyglycolic acid Substances 0.000 description 6
- 239000004926 polymethyl methacrylate Substances 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 6
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000002679 ablation Methods 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229960004562 carboplatin Drugs 0.000 description 4
- 190000008236 carboplatin Chemical compound 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- 229960005277 gemcitabine Drugs 0.000 description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
- 238000001361 intraarterial administration Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229960003787 sorafenib Drugs 0.000 description 4
- 239000004952 Polyamide Substances 0.000 description 3
- 239000000560 biocompatible material Substances 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000002767 hepatic artery Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910001092 metal group alloy Inorganic materials 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920000052 poly(p-xylylene) Polymers 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 2
- 206010060965 Arterial stenosis Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 229960002412 cediranib Drugs 0.000 description 2
- 210000001627 cerebral artery Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 229960000961 floxuridine Drugs 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 2
- 229960001420 nimustine Drugs 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 210000002254 renal artery Anatomy 0.000 description 2
- 210000002563 splenic artery Anatomy 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- 229960000241 vandetanib Drugs 0.000 description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 108010027529 Bio-glue Proteins 0.000 description 1
- 206010064687 Device related infection Diseases 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010062546 Thrombosis in device Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002434 celiac artery Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000002710 external beam radiation therapy Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229940084910 gliadel Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000001465 metallisation Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000006510 metastatic growth Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000637 radiosensitizating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/003—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles having a lumen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/12—Blood circulatory system
Abstract
Description
本発明では、以下の用語は、次のように理解されるものとする:
− 「約」:数字の前に付けられ、この数字の公称値のプラス又はマイナス10%、好ましくはこの数字の公称値のプラス又はマイナス5%を意味する。
本発明は、少なくとも1つのマイクロ流体チャネル(121)を備えるマイクロ流体チップ(13)と、少なくとも1つのマイクロ流体チャネル(121)と流体接続する少なくとも2つの中空マイクロニードル(11)を備えるカバー(14)とを備える、流体の局所領域注入及び/又はサンプリングのための植込み可能な医療装置(1)に関する。図1は、このような局所領域注入及び/又はサンプリングのための植込み可能な医療装置の一実施形態を示す。
11−マイクロニードル
12−二次パス
121−マイクロ流体チャネル
13−マイクロ流体チップ
14−カバー
2−注入/サンプリング装置
3−一次パス
4−実質
5−血管
Claims (14)
- マイクロ流体チップ(13)とカバー(14)とを備える、血管(5)の管腔内又は実質(4)内での局所領域注入及び/又はサンプリングのための植込み可能な医療装置(1)であって、前記マイクロ流体チップ(13)は、前記マイクロ流体チップ(13)の第1の面から前記マイクロ流体チップ(13)の第2の面に延びる少なくとも1つのマイクロ流体チャネル(121)を備え、前記カバー(14)は、前記カバー(14)から突き出る少なくとも2つの中空マイクロニードル(11)を備え、前記カバー(14)は、前記少なくとも1つのマイクロ流体チャネル(121)が前記少なくとも2つの中空マイクロニードル(11)と流体接続するように前記マイクロ流体チップ(13)の第2の面に固定され、前記カバー(14)から突き出る少なくとも2つの中空マイクロニードル(11)の長さは、前記カバー(14)が血管(5)の外壁上又は実質(4)上に植込まれるときに前記少なくとも2つの中空マイクロニードル(11)の端が血管(5)の管腔又は実質(4)に貫入するように構成される、装置。
- 前記マイクロ流体チップ(13)の材料と前記カバー(14)の材料が、可塑的に適合可能である、好ましくは血管(5)又は実質(4)の形状に順応するように血管(5)又は実質(4)の外面に可塑的に適合可能である、請求項1に記載の装置。
- 前記マイクロ流体チップ(13)と前記カバー(14)が、湾曲した形状に予備成形される、請求項1に記載の装置。
- 前記マイクロ流体チップ(13)の第1の面と前記マイクロ流体チップ(13)の第2の面が別個のものである、請求項1乃至3のいずれかに記載の装置。
- 前記マイクロ流体チップ(13)が、上面、底面、及び側面を備え、前記第1の面が側面であり、前記第2の面が上面又は底面である、請求項4に記載の装置。
- 前記マイクロ流体チップ(13)が、上面、底面、及び側面を備え、前記第1の面が上面であり、前記第2の面が底面である、請求項4に記載の装置。
- 前記カバー(14)が、少なくとも5、10、20、50、又は100個の中空マイクロニードル(11)を備え、各中空マイクロニードル(11)が少なくとも1つのマイクロ流体チャネル(121)と流体接続する、請求項1乃至6のいずれかに記載の装置。
- 前記少なくとも1つのマイクロ流体チャネル(121)が、カテーテルなどの一次流体注入又はサンプリングパス(3)に接続される、請求項1乃至7のいずれかに記載の装置。
- 前記マイクロ流体チップ(13)が少なくとも2つのマイクロ流体チャネル(121)を備える、請求項1乃至8のいずれかに記載の装置。
- 前記マイクロ流体チップ(13)が少なくとも2つのマイクロ流体回路を備える、請求項9に記載の装置。
- 各マイクロ流体回路が別個の一次パス(3)に接続される、請求項10に記載の装置。
- 請求項1乃至11のいずれかに記載の装置によってそれを必要とする患者に投与されることを特徴とする、肝腫瘍又は肝転移を治療するための抗腫瘍性抗生物質、微小管阻害剤、プロテインキナーゼ阻害剤、白金製剤、代謝拮抗剤、siRNA、又は放射線増感剤。
- 請求項1乃至11のいずれかに記載の装置によってそれを必要とする患者に投与されることを特徴とする、脳腫瘍を治療するためのアルキル化剤、プロテインキナーゼ阻害剤、白金製剤、EGFR阻害剤、VEGF阻害剤、トポイソメラーゼ阻害剤、代謝拮抗剤、siRNA、又は放射線増感剤。
- 請求項1乃至11のいずれかに記載の装置によってそれを必要とする患者に投与されることを特徴とする、膵腫瘍を治療するための抗腫瘍性抗生物質、微小管阻害剤、白金製剤、代謝拮抗剤、siRNA、又は放射線増感剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1656954 | 2016-07-21 | ||
FR1656954A FR3054137B1 (fr) | 2016-07-21 | 2016-07-21 | Dispositif medical implantable d’injection locoregionale |
PCT/FR2017/052013 WO2018015690A1 (fr) | 2016-07-21 | 2017-07-21 | Dispositif médical implantable d'injection locorégionale |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019524253A true JP2019524253A (ja) | 2019-09-05 |
JP7183145B2 JP7183145B2 (ja) | 2022-12-05 |
Family
ID=57396573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019502558A Active JP7183145B2 (ja) | 2016-07-21 | 2017-07-21 | 局所領域注入のための植込み可能な医療装置 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210178136A1 (ja) |
EP (1) | EP3487575A1 (ja) |
JP (1) | JP7183145B2 (ja) |
CN (1) | CN109475729A (ja) |
CA (1) | CA3031316A1 (ja) |
FR (1) | FR3054137B1 (ja) |
WO (1) | WO2018015690A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010502267A (ja) * | 2006-08-28 | 2010-01-28 | エージェンシー・フォー・サイエンス・テクノロジー・アンド・リサーチ | マイクロニードルおよびマイクロニードルの製造方法 |
WO2010067882A1 (ja) * | 2008-12-12 | 2010-06-17 | 株式会社クレハ | 癌及び喘息治療のための医薬組成物 |
JP2010168368A (ja) * | 2008-12-26 | 2010-08-05 | Taisho Pharmaceutical Co Ltd | Psma7、nedd1およびrae1遺伝子発現抑制剤の用途 |
JP2011078654A (ja) * | 2009-10-09 | 2011-04-21 | Asti Corp | マイクロニードルアレイとマイクロニードルアレイの製造方法 |
US20130345671A1 (en) * | 2011-03-04 | 2013-12-26 | Industry-Academic Cooperation Foundation Yonsei University | Microneedle-containing drug delivery device to be attached to exterior wall of vascular vessel and method for drug delivery therewith |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7070590B1 (en) | 1996-07-02 | 2006-07-04 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
US5797898A (en) | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
EP1140275A1 (en) * | 1998-12-18 | 2001-10-10 | Minimed Inc. | Insertion sets with micro-piercing members for use with medical devices and methods of using the same |
CN2654137Y (zh) * | 2003-11-04 | 2004-11-10 | 浙江大学 | 一种基于微加工技术的无痛微针阵列 |
US8206334B2 (en) * | 2006-01-31 | 2012-06-26 | Kralick Francis A | Implantable micro-system for treatment of hydrocephalus |
CN1830496A (zh) * | 2006-04-10 | 2006-09-13 | 清华大学 | “-”字形结构三维微型实心、空心硅针或刀 |
CN100998901B (zh) * | 2007-01-12 | 2012-10-10 | 中国科学院上海微系统与信息技术研究所 | 多孔硅无痛注射微针阵列及其制备方法 |
US20090074831A1 (en) * | 2007-09-18 | 2009-03-19 | Robert Falotico | LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS |
US20100256569A1 (en) | 2007-10-27 | 2010-10-07 | Debiotech S.A. | Medical injection device with microneedles |
US8808255B2 (en) * | 2007-12-14 | 2014-08-19 | Oregon Health & Science University | Drug delivery cuff |
KR20110086854A (ko) * | 2008-11-18 | 2011-08-01 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 중공 마이크로니들 어레이 및 방법 |
CN101879336A (zh) * | 2009-05-06 | 2010-11-10 | 中国科学院半导体研究所 | 用于皮下药物注射的基于柔性基底的微针阵列及其制法 |
EP2275164A1 (en) | 2009-07-15 | 2011-01-19 | Debiotech S.A. | Multichannel micro-needles |
WO2011135531A2 (en) * | 2010-04-28 | 2011-11-03 | Kimberly-Clark Worldwide, Inc. | MEDICAL DEVICES FOR DELIVERY OF siRNA |
CN101912663B (zh) * | 2010-08-18 | 2013-09-04 | 清华大学 | 空心微针阵列芯片、经皮给药贴片、器件及制备方法 |
CN102453713B (zh) * | 2010-10-20 | 2014-02-19 | 中国医学科学院肿瘤研究所 | HULC siRNA及其在制备治疗肝癌的药物中的用途 |
US20140052067A1 (en) * | 2011-03-18 | 2014-02-20 | Universite Libre De Bruxelles | Devices for puncturing for a human or animal body's membrane |
AU2012326664A1 (en) * | 2011-09-02 | 2014-04-03 | North Carolina State University | Microneedle arrays for biosensing and drug delivery |
CN103570594A (zh) * | 2012-08-01 | 2014-02-12 | 苏州迈泰生物技术有限公司 | 二芳基胺类化合物及其在制备抗恶性肿瘤药物中的用途 |
CN104004822B (zh) * | 2013-02-27 | 2018-08-07 | 霍克克 | Ssx2ip在预测或诊断肿瘤转移中的应用 |
CN104043192B (zh) * | 2014-06-28 | 2016-08-24 | 陈彦彪 | 一次性微针装置 |
CN105381536A (zh) * | 2015-12-22 | 2016-03-09 | 无锡吉迈微电子有限公司 | 自行载药的长时透皮给药及取样装置 |
-
2016
- 2016-07-21 FR FR1656954A patent/FR3054137B1/fr not_active Expired - Fee Related
-
2017
- 2017-07-21 WO PCT/FR2017/052013 patent/WO2018015690A1/fr unknown
- 2017-07-21 CN CN201780045154.4A patent/CN109475729A/zh active Pending
- 2017-07-21 EP EP17754405.3A patent/EP3487575A1/fr active Pending
- 2017-07-21 CA CA3031316A patent/CA3031316A1/fr not_active Abandoned
- 2017-07-21 US US16/319,686 patent/US20210178136A1/en not_active Abandoned
- 2017-07-21 JP JP2019502558A patent/JP7183145B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010502267A (ja) * | 2006-08-28 | 2010-01-28 | エージェンシー・フォー・サイエンス・テクノロジー・アンド・リサーチ | マイクロニードルおよびマイクロニードルの製造方法 |
WO2010067882A1 (ja) * | 2008-12-12 | 2010-06-17 | 株式会社クレハ | 癌及び喘息治療のための医薬組成物 |
JP2010168368A (ja) * | 2008-12-26 | 2010-08-05 | Taisho Pharmaceutical Co Ltd | Psma7、nedd1およびrae1遺伝子発現抑制剤の用途 |
JP2011078654A (ja) * | 2009-10-09 | 2011-04-21 | Asti Corp | マイクロニードルアレイとマイクロニードルアレイの製造方法 |
US20130345671A1 (en) * | 2011-03-04 | 2013-12-26 | Industry-Academic Cooperation Foundation Yonsei University | Microneedle-containing drug delivery device to be attached to exterior wall of vascular vessel and method for drug delivery therewith |
Also Published As
Publication number | Publication date |
---|---|
CN109475729A (zh) | 2019-03-15 |
CA3031316A1 (fr) | 2018-01-25 |
WO2018015690A1 (fr) | 2018-01-25 |
FR3054137A1 (fr) | 2018-01-26 |
JP7183145B2 (ja) | 2022-12-05 |
FR3054137B1 (fr) | 2021-08-27 |
US20210178136A1 (en) | 2021-06-17 |
EP3487575A1 (fr) | 2019-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Appelboom et al. | Stereotactic modulation of blood-brain barrier permeability to enhance drug delivery | |
US8267905B2 (en) | Apparatus and method for delivery of therapeutic and other types of agents | |
JP4604022B2 (ja) | 運搬促進デリバリー法による組織および腫瘍への液体の投与のための携帯用装置 | |
Chua et al. | Emerging technologies for local cancer treatment | |
JP6929331B2 (ja) | 骨内インフュージョンポートおよび使用方法 | |
EP3624794A1 (en) | Methods for treating cancerous tumors | |
US20070225544A1 (en) | Apparatuses and techniques for bioactive drug delivery in the prostate gland | |
US11052224B2 (en) | Methods for treating cancerous tumors | |
US20110046540A1 (en) | Apparatus for Trans-Cerebral Electrophoresis and Methods of Use Thereof | |
JP5449872B2 (ja) | 拍動流薬物送達 | |
US20160136284A1 (en) | Glioma treatment | |
JP2017524418A (ja) | 左胃動脈の遠位部分への粒子の選択的な送達 | |
US20190151239A1 (en) | Infusing drug solution directly into brain fluid | |
US20150038902A1 (en) | Infusion therapy device | |
WO2003002170A2 (en) | Minimally invasive drug delivery catheter | |
JP2015015988A (ja) | 医療用器具 | |
JP7183145B2 (ja) | 局所領域注入のための植込み可能な医療装置 | |
WO2014128875A1 (ja) | 医療用器具 | |
WO2014128824A1 (ja) | 医療用器具 | |
Yearley et al. | Implantable microdevices for treating brain tumors | |
JP2015015989A (ja) | 医療用器具 | |
Jain et al. | Methods of Drug Delivery to the Nervous System and DIND | |
Patta | Local exposure and efficacy of a reservoir-based drug delivery device | |
Saka et al. | Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India | |
JP2023514338A (ja) | 体内の治療部位への薬剤の送達 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200626 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210324 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210330 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210615 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211130 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220526 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221004 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221024 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221122 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7183145 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |